000276097 001__ 276097
000276097 005__ 20250121165738.0
000276097 0247_ $$2doi$$a10.5281/ZENODO.14055918
000276097 037__ $$aDZNE-2025-00178
000276097 041__ $$aEnglish
000276097 1001_ $$0P:(DE-2719)2811745$$aGilsbach, Bernd$$b0$$udzne
000276097 245__ $$aDataset: Supplemental data for 'Intramolecular feedback regulation of the LRRK2 Roc G domain by a LRRK2 kinase dependent mechanism' (Gilsbach et al., eLife 2024, doi:10.7554/eLife.91083), v3
000276097 260__ $$bZenodo$$c2024
000276097 3367_ $$2BibTeX$$aMISC
000276097 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1737454042_5211
000276097 3367_ $$026$$2EndNote$$aChart or Table
000276097 3367_ $$2DataCite$$aDataset
000276097 3367_ $$2ORCID$$aDATA_SET
000276097 3367_ $$2DINI$$aResearchData
000276097 520__ $$aSupportive data for the eLife version of record. (1) Data used for the Michaelis Menten Kinetics. HPLC-based assay. Steady-state kinetic measurements of LRRK2-mediated GTP hydrolysis were performed as previously described (Ahmadian et al., 1997). Briefly, 0.1 µM of full-length LRRK2 was incubated with different amounts of GTP (0, 25, 75, 150, 250, 500, 1000, 2000, 3000 and 5000 µM) and production of GDP was monitored by reversed phase C18 HPLC. To this end, the samples (10 µl) were directly injected on a reversed-phase C18 column (pre-column: Hypersil Gold, 3µm particle size, 4.6x10mm; main column: Hypersil Gold, 5µm particle size, 4.6x250mm, Thermo Scientific) using an Ultimate 3000 HPLC system (Thermo Scientific, Waltham, MA, USA) in HPLC-buffer containing 50 mM KH2PO4/K2HPO4 pH 6.0, 10 mM tetrabutylammonium bromide and 10-15% acetonitrile. Subsequently, samples were analyzed using the HPLC integrator (Chromeleon 7.2, Thermo Scientific, Waltham, MA, USA). Initial rates of GDP production were plotted against the GTP concentration using GraFit5 (v.5.0.13, Erithacus Software). The number of experiments is indicated in the graph and data point is the average (±s.e.m.) of indicated repetitions. The Michaelis-Menten equation was fitted to determine KM (±s.e.) and kcat (±s.e.). Excel sheets used for the calculation of means are provided. No values are reported if the HPLC separation failed (e.g. unstable baseline). Charcoal GTP hydrolysis assay. The [γ-32P]GTP charcoal assay was performed as previously described (Bollag and McCormick, 1995). Briefly, 0.1 µM full-length LRRK2 or 0.5 µM 6xHIS-MBP-RocCOR was incubated with different GTP concentrations, ranging from 75 µM to 8 mM, in the presence of [γ-32P] GTP in GTPase assay buffer (30 mM Tris pH 8, 150 mM NaCl, 10 mM MgCl2, 5% (v/v) Glycerol and 3 mM DTT). Samples were taken at different time-points and immediately quenched with 5% activated charcoal in 20 mM phosphoric acid. All non-hydrolyzed GTP and proteins were stripped by the activated charcoal and sedimented by centrifugation. The radioactivity of the isolated inorganic phosphates was then measured by scintillation counting. The initial rates of γ-phosphate release and the Michaelis-Menten kinetics were calculated as described above. (2) Profile plots (Raw data) obtained for the Mass photometry analysis for T1343A vs WT LRRK2. MP was performed as described in (Guaitoli et al., 2023). Briefly, the dimer ratio of LRRK2 was determined on a Refeyn Two MP instrument (Refeyn). Prior to the experiment, a standard curve relating particle contrasts to molecular weight was established using a Native molecular weight standard (Invitrogen, 1:200 dilution in HEPES-based elution buffer: 50 mM HEPES [pH 8.0], 150 mM NaCl supplemented with 200 µM desthiobiotin). Prior to mass photometry, the proteins, either WT or T1343A LRRK2, were incubated with 0.5 mM ATP or buffer (control) for 30 min at 30 ℃. The LRRK2 protein was diluted to 2x of the final concentration (end concentrations: 75 nM and 100 nM) in elution buffer. The optical setup was focused in 10 μl elution buffer before adding 10 µl of the adjusted protein sample. Depending on the obtained count numbers, acquisition times were chosen between 20 s to 1 min. The dimer ratio in each measurement was normalize according to the equation. The measurement was perfomed in triplicates. (3) AlphaFold3 model of LRRK2-pT1343 either bound to GDP/Mg or GTP/Mg. Using AlphaFold3 (Abramson et al., 2024), we modeled and compared the GDP vs the GTP-state of phospho-T1343 LRRK2. Interestingly, the AlphaFold3 model suggests, that the phosphate group of the pT1343 residue is orientated inwards thereby substituting the gamma phosphate of the GTP in the GDP-bound state of LRRK2. This finding is in well agreement with MD simulations published recently (Stormer et al., 2023). (4) Western blot RAW files for the cell-based phospho Rab asssay (RAW data for Figure 6 supplement 2/ Supplemental Figure 4 in the preprint version, Gilsbach et al, 2024) Cell-based LRRK2 activity assays were performed as previously described (Singh et al., 2022). Briefly, HEK293T cells were cultured in DMEM (supplemented with 10% Fetal Bovine Serum and 0.5% Pen/Strep). For the assay, the cells were seeded onto six-well plates and transfected at a confluency of 50-70% with SF-tagged LRRK2 variants using PEI-based lipofection. After 48 hours cells were lysed in lysis buffer [30 mM Tris-HCl (pH7.4), 150 mM NaCl, 1% NonidentP-40 substitute, complete protease inhibitor cocktail, PhosStop phosphatase inhibitors (Roche)]. Lysates were cleared by centrifugation at 10,000 x g and adjusted to a protein concentration of 1 µg/µl in 1x Laemmli Buffer. Samples were subsequently subjected to SDS PAGE and Western Blot analysis to determine LRRK2 pS935 and Rab10 T73 phosphorylation levels, as described below. Total LRRK2 and Rab10 levels were determined as a reference for normalization. For Western blot analysis, protein samples were separated by SDS–PAGE using NuPAGE 10% Bis-Tris gels (Invitrogen) and transferred onto PVDF membranes (Thermo Fisher). To allow simultaneous probing for LRRK2 on the one hand and Rab10 on the other hand, membranes were cut horizontally at the 140 kDa MW marker band. After blocking non-specific binding sites with 5% non-fat dry milk in TBST (1 h, RT) (25 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween-20), membranes were incubated overnight at 4°C with primary antibodies at dilutions specified below. Phospho-specific antibodies were diluted in TBST/ 5% BSA (Roth GmbH). Non-phospho-specific antibodies were diluted in TBST/ 5% non-fat dry milk powder (BioRad). Phospho-Rab10 levels were determined by the site-specific rabbit monoclonal antibody anti-pRAB10(pT73) (Abcam, ab230261) and LRRK2 pS935 was determined by the site-specific rabbit monoclonal antibody UDD2 (Abcam, ab133450), both at a dilution of 1:2,000. Total LRRK2 levels were determined by the in-house rat monoclonal antibody anti-pan-LRRK2 (clone 24D8; 1:10,000) (Carrion et al., 2017). Total Rab10 levels were determined by the rabbit monoclonal antibody anti-RAB10/ERP13424 (Abcam, ab181367) at a dilution of 1:5,000. For detection, goat anti-rat IgG or anti-rabbit IgG HRP-coupled secondary antibodies (Jackson ImmunoResearch) were used at a dilution of 1:15,000 in TBST/ 5% non-fat dry milk powder. Antibody–antigen complexes were visualized using the ECL plus chemiluminescence detection system (GE Healthcare) using the Stella imaging system (Raytest) for detection and quantification. Figure 6 Source Data 1: Images generated by the Stella system are shown which were used for quantification. The annotation file equals Figure6-figure supplement 2 (Gilsbach et al., eLife 2024, doi:10.7554/eLife.91083). The lines corresponding to LRRK2 pS935, total LRRK2, Rab10 pT73 and total Rab10 were used for the quantification shown in Figure 6.
000276097 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000276097 588__ $$aDataset connected to DataCite
000276097 650_7 $$2Other$$astructural modeling
000276097 650_7 $$2Other$$aLRRK2
000276097 7001_ $$00000-0003-3663-2889$$aHo, Franz Y.$$b1
000276097 7001_ $$00009-0005-1579-6851$$aZhang, Xiaojuan$$b2
000276097 7001_ $$00000-0001-8174-6397$$aKortholt, Arjan$$b3
000276097 7001_ $$0P:(DE-2719)2811291$$aGloeckner, Christian Johannes$$b4
000276097 773__ $$a10.5281/ZENODO.14055918
000276097 8564_ $$uhttps://pub.dzne.de/record/276097/files/DZNE-2025-00178.zip
000276097 909CO $$ooai:pub.dzne.de:276097$$pVDB
000276097 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811745$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000276097 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811291$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000276097 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000276097 9201_ $$0I:(DE-2719)1210007$$kAG Gloeckner$$lFunctional Neuroproteomics and Translational Biomarkers in Neurodegenerative Diseases$$x0
000276097 980__ $$adataset
000276097 980__ $$aVDB
000276097 980__ $$aI:(DE-2719)1210007
000276097 980__ $$aUNRESTRICTED